Focused On-demand Library for Interferon gamma receptor 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

P15260

UPID:

INGR1_HUMAN

Alternative names:

CDw119; Interferon gamma receptor alpha-chain

Alternative UPACC:

P15260; B4DFT7; E1P587; Q53Y96

Background:

Interferon gamma receptor 1 (IFNGR1), also known as CDw119, plays a pivotal role in immune responses against infections and tumors. It forms a functional receptor with IFNGR2, crucial for activating immune cells and enhancing antigen presentation. Upon binding with interferon gamma, IFNGR1 initiates a cascade involving JAK1 and JAK2 phosphorylation, leading to STAT1 activation and gene transcription essential for antimicrobial, antiviral, and antitumor responses.

Therapeutic significance:

Mutations in IFNGR1 are linked to Immunodeficiency 27A and 27B, conditions characterized by impaired interferon-gamma mediated immunity, leading to susceptibility to mycobacterial diseases. Understanding the role of IFNGR1 could open doors to potential therapeutic strategies for these immunodeficiencies, offering hope for targeted treatments that restore immune function and prevent severe infections.